A Study of Pancreatic Cancer in Xenografts From Liver Metastases

University Health Network, Toronto31 enrolled

Overview

This is a feasibility study to perform image-guided liver biopsies in 25 patients who have pancreatic cancer with liver metastasis (cancer in the pancreas that has spread to the liver). This will contribute with samples for the bio-bank (bank of tumors) and develop xenografts (human tumors growing in mice) for further analysis of genes.

This study might bring a better understanding of the metastatic pancreatic cancer and evaluate the differences between the metastatic and the primary pancreatic cancer (the type that does not have metastasis).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pancreatic Cancer Liver Metastases Tumor Tissue Biopsy Blood Samples

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Minimum age of 18 years old * Pancreatic cancer with liver metastasis * No contraindication to image-guided biopsy of liver metastasis, including uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine etc) and no significant hepatic dysfunction. * Provide written informed consent * ECOG 0,1 or 2 Exclusion Criteria: * Inability to lie supine for more than 30 minutes * ECOG 3 or more * Serious medical risk factors involving any of the major organ systems or including uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine etc) and no significant hepatic dysfunction.

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Number of patients with adverse events due to biopsies

Monitoring adverse events during trial related to biopsies

Time frame: up to 2 years

Number of successful xenografts

determine the "take rate" or success of establishing xenografts

Time frame: up to 2 years

Number of similarities and differences between original patient tumor sample with xenograft sample

complete histological and molecular comparison of original patient sample with murine xenograft

Time frame: up to 2 years

Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)

determine the correlation between engraftment rate and clinical data (response to treatment, disease-free survival, overall survival).

Time frame: up to date of death from any cause

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.